🏢 官网IRCNMDCodex · 实盘不做把握 3/10
北京时间·🕒 发布 19:00:00时区推断·⟳ 抓取 19:02:08回填·⚡ 决策 07-20 19:04:09·99.1 天前
CONMED将参加机器人外科年会并展示AirSeal既有临床试验结果
这是公司IR发布的会议参与公告，核心临床试验结果已于2026年5月公开发表，本次只是年会展示与教育场次安排。
📄 原文CNMD↗ 原文
CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting
Skip to main navigation News Release View printer-friendly version « Back July 20, 2026 at 7:00 AM EDT CONMED Corporati…
不做 CONMED Corporation（CNMD.US）
公司会议参与公告且核心试验结果已于2026年5月发表，无新订单、审批、收入指引或可量化商业化增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-20 · 扩散 low · price-in 风险 high ↗
关键理由
- 这是公司IR发布的会议参与公告，核心临床试验结果已于2026年5月公开发表，本次只是年会展示与教育场次安排。
- 事件未披露新订单、监管批准、商业化放量、收入指引或其他可量化增量，难以形成短线重定价催化。
主要风险
- 若会议期间后续披露新的商业合作、采购订单或监管进展，需要按新事件重新研判。
原文全文
展开原文 · 4,481 字
Skip to main navigation
News Release
View printer-friendly version
« Back
July 20, 2026 at 7:00 AM EDT
CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting
Professor Nikhil Vasdev to Present Results of a Recently Published Clinical Trial Featuring AirSeal ® technology
LARGO, Fla. --(BUSINESS WIRE)--Jul. 20, 2026--
CONMED Corporation (NYSE: CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL.
During the meeting, Professor Nikhil Vasdev, FRCS (Urol), MCh (Urol), DSc will present data from a prospective randomized controlled clinical trial conducted by Vasdev et al., which investigated differences in the levels of intraoperative and post-operative pain between two abdominal insufflators, CONMED’s AirSeal ® Insufflation System and Stryker’s PneumoClear Insufflator.
TITLE: Utilising intra-operative artificial intelligence to investigate the difference in nociceptive stimulus between 2 different abdominal insufflators during a Robotic Prostatectomy (RALP Clinical Trial)
DATE: Friday, July 24
TIME: 8:02 AM ET
LOCATION: 314
The trial included 40 patients with localized prostate cancer who underwent a robotic prostatectomy, with either AirSeal or PneumoClear used for the management of low-pressure pneumoperitoneum (8 mmHg). Differences in the levels of significant intra-operative nociception between the two insufflators were recorded using an artificial intelligence device. The AirSeal arm of the trial had fewer significant nociceptive events per recorded hour than the PneumoClear arm (20.7 vs. 33.5, p = 0.041). Additionally, shorter procedure times (p = 0.045), console times (p = 0.045), and blood loss (p < 0.001) were seen in the AirSeal arm. The results of the trial were published in the open access journal, JUI Compass , in May, 2026 and are available via the following link: https://bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bco2.70226
In connection with its participation, CONMED will host a session that explores how low-pressure insufflation is redefining intraoperative performance to support surgical efficiency and enable enhanced patient recovery. The session will feature Amit Taggar , MD, FACS, FAMBS, FICS, Gabe Mena , MD FASA, Philip Woodworth , MD, FACS, and Rahila Essani , MD, FACS, FACRS.
TITLE: Why Stability at Low Pressure in Robotic Surgery Matters Intraoperatively and for Patients
DATE: Friday, July 24
TIME: 12:30 PM ET
LOCATION: Diplomat Room 4
About CONMED Corporation
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com .
Forward-Looking Statements
This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260720880337/en/
CONMED Corporation
Dalton Henry
Investor Relations Analyst
IR@conmed.com
Source: CONMED Corporation
News Release
View printer-friendly version
« Back
July 20, 2026 at 7:00 AM EDT
CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting
Professor Nikhil Vasdev to Present Results of a Recently Published Clinical Trial Featuring AirSeal ® technology
LARGO, Fla. --(BUSINESS WIRE)--Jul. 20, 2026--
CONMED Corporation (NYSE: CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL.
During the meeting, Professor Nikhil Vasdev, FRCS (Urol), MCh (Urol), DSc will present data from a prospective randomized controlled clinical trial conducted by Vasdev et al., which investigated differences in the levels of intraoperative and post-operative pain between two abdominal insufflators, CONMED’s AirSeal ® Insufflation System and Stryker’s PneumoClear Insufflator.
TITLE: Utilising intra-operative artificial intelligence to investigate the difference in nociceptive stimulus between 2 different abdominal insufflators during a Robotic Prostatectomy (RALP Clinical Trial)
DATE: Friday, July 24
TIME: 8:02 AM ET
LOCATION: 314
The trial included 40 patients with localized prostate cancer who underwent a robotic prostatectomy, with either AirSeal or PneumoClear used for the management of low-pressure pneumoperitoneum (8 mmHg). Differences in the levels of significant intra-operative nociception between the two insufflators were recorded using an artificial intelligence device. The AirSeal arm of the trial had fewer significant nociceptive events per recorded hour than the PneumoClear arm (20.7 vs. 33.5, p = 0.041). Additionally, shorter procedure times (p = 0.045), console times (p = 0.045), and blood loss (p < 0.001) were seen in the AirSeal arm. The results of the trial were published in the open access journal, JUI Compass , in May, 2026 and are available via the following link: https://bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bco2.70226
In connection with its participation, CONMED will host a session that explores how low-pressure insufflation is redefining intraoperative performance to support surgical efficiency and enable enhanced patient recovery. The session will feature Amit Taggar , MD, FACS, FAMBS, FICS, Gabe Mena , MD FASA, Philip Woodworth , MD, FACS, and Rahila Essani , MD, FACS, FACRS.
TITLE: Why Stability at Low Pressure in Robotic Surgery Matters Intraoperatively and for Patients
DATE: Friday, July 24
TIME: 12:30 PM ET
LOCATION: Diplomat Room 4
About CONMED Corporation
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com .
Forward-Looking Statements
This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260720880337/en/
CONMED Corporation
Dalton Henry
Investor Relations Analyst
IR@conmed.com
Source: CONMED Corporation
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。